Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in Ret transgenic mice spontaneously developing melanoma

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4382-4390

  Zhao, Fang ^a   Falk, Christine ^b   Osen, Wolfram ^a   Kato, Masashi ^c   Schadendorf, Dirk ^a,d   Umansky, Viktor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c CHUBU UNIVERSITY   (Japan)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12P70; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN RET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LEUKOCYTE COUNT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; DENDRITIC CELLS; DISEASE PROGRESSION; ENZYME ACTIVATION; IMMUNE TOLERANCE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-RET; TUMOR BURDEN; TUMOR ESCAPE;

EID: 67650354587     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0399     Document Type: Article

References (49)

1. Steinman RM. Dendritic cells: versatile controllers of the immune system. NatMed 2007;13:1155-9.
2. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007;220:129-50.
3. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. HumanTcell responses againstmelanoma. Annu Rev Immunol 2006;24:175-208.
4. Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future.Curr Opin Oncol 2007;19:121-7.
5. Mayordomo JI. Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.NatMed 1995;1:1297-302.
6. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ.Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006;90: 175-213.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. NatMed 1998;4:328-32.
8. SchulerG, Schuler-Thurner B, Steinman R.The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
9. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC studygr oup of the DeCOG. Ann Oncol 2006;17:563-70.
10. Kusmartsev S, Gabrilovich DI. Effect of tumorderived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. CancerMetastasis Rev 2006;25:323-31.
11. ZouW. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
12. + anergic T cells induced by interleukin-10-treated human dendritic cells displayan tigenspecific suppressoractivity.Blood2002;99:2468-76.
13. Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-4 on APCs through IL-10: novel suppressive mode for regulatory Tcells. J Immunol 2006;177: 40-4.
14. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells intoTGF-hsecreting cells inducing CD4+CD25+ regulatoryT cell proliferation. JExpMed 2005;202:919-29.
15. Kato M, Takahashi M, Akhand AA, et al. Transgenic mousemodel for skinmalignantmelanoma.Oncogene 1998;17:1885-8.
16. Kato M, Takeda K, Kawamoto Y, et al. c-Kit-targeting immunotherapyf or hereditary melanoma in a mouse model. Cancer Res 2004;64:801-6.
17. Houghton A, Polsky D. Focus onmelanoma. Cancer Cell 2002;2:275-8.
18. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162:168-75.
19. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
20. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
21. RattaM, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
22. Maecker B, Mougiakakos D, Zimmermann M, et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006;20:645-9.
23. Sakakura K, Chikamatsu K,Takahashi K,Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006;55:151-9.
24. Ormandy LA, Farber A, Cantz T, et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006;12: 3275-82.
25. Pinzon-Charry A, Ho CS, Maxwell T, et al.Numerical and functional defects of blood dendritic cells in earlyand late-stage breast cancer. Br J Cancer 2007;97: 1251-9.
26. Bellik L, Gerlini G, Parenti A, et al. Role of conventional treatments on circulating andmonocyte-derived dendritic cells in colorectal cancer. Clin Immunol 2006;121:74-80.
27. Esche C, Lokshin A, Shurin GV, et al. Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999; 66:336-44.
28. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and earlya poptosis of monocyte-derived dendritic cells. J Immunol 2000;164:1269-76.
29. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol 2001;167:3773-84.
30. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190:1417-26.
31. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM, Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001;61:363-9.
32. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
33. Perrot I, Blanchard D, Freymond N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178:2763-9.
34. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression bymy eloid derived suppressor cells. Immunol Rev 2008;222:162-79.
35. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed bymyeloid-derived suppressor cells.Cancer Res 2008;68:2561-3.
36. Pirtskhalaishvili G, Shurin GV, Gambotto A, et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 2000;165: 1956-64.
37. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
38. Mahnke K, Enk A. Dendritic cells: key cells for the induction of regulatory T cells? Curr. Top. Microbiol Immunol 2005;293:133-50.
39. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor byh uman tumors inhibits the functional maturation of dendritic cells. NatMed 1996;2:1096-103.
40. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004;165: 1853-63.
41. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66: 5527-36.
42. von Felbert V, Córdoba F,Weissenberger J, et al. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 2005;166:831-41.
43. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses byS tat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
44. Escors D, Lopes L, Lin R, et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008;111:3050-61.
45. Wang S, Hong S, Yang J, et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006;108:4071-7.
46. Jarnicki AG, Conroy H , Brereton C, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797-806.
47. Ashwell JD. Themanypaths top 38 mitogen-activated proteinkinase activation in the immune system.NatRev Immunol 2006;6:532-40.
48. Adler HS, Kubsch S, Graulich E, Ludwig S, Knop J, Steinbrink K. Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatoryT cells. Blood 2007;109:4351-9.
49. Merritt C, Enslen H, Diehl N, Conze D, Davis RJ, Rincón M. Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8(+) but not CD4(+) T cells. Mol Cell Biol 2000;20:936-46.